Biofrontera Q2 2024 GAAP EPS $(0.05), Sales $7.84M Miss $8.21M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biofrontera (NASDAQ:BFRI) reported Q2 2024 GAAP EPS of $(0.05) and sales of $7.84 million, missing the analyst estimate of $8.21 million. Despite the miss, sales increased by 34.05% compared to the same period last year.
August 14, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biofrontera reported Q2 2024 GAAP EPS of $(0.05) and sales of $7.84 million, missing the analyst estimate of $8.21 million. Sales increased by 34.05% YoY.
The miss on both EPS and sales estimates is likely to negatively impact the stock price in the short term. However, the significant YoY sales growth may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100